Sellas Life Sciences Group (SLS) attracts speculative interest from growth investors due to its advanced cancer immunotherapy pipeline, including Phase 3 clinical candidates like galinpepimut-S. While some analysts maintain strong buy ratings based on the potential addressable oncology market, financial risk evaluators caution that micro-cap biotech firms face severe capital-raising demands, high volatility, and clinical trial execution risks that require extensive due diligence before committing investment funds.